Ekterly (sebetralstat) for hereditary angioedema: the first FDA-approved oral on-demand therapy

Dua Asim, Zoha Idrees, Muhammad Anas Faheem, Jaber Hamad Jaber Amin

Open source

DOI
10.1097/ms9.0000000000005115
Published
2026-05-19
Container
Annals of Medicine & Surgery
Publisher
Ovid Technologies (Wolters Kluwer Health)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1097/ms9.0000000000005115,
  title = {Ekterly (sebetralstat) for hereditary angioedema: the first FDA-approved oral on-demand therapy},
  author = {Dua Asim and Zoha Idrees and Muhammad Anas Faheem and Jaber Hamad Jaber Amin},
  year = {2026},
  journal = {Annals of Medicine \& Surgery},
  doi = {10.1097/ms9.0000000000005115},
  url = {https://doi.org/10.1097/ms9.0000000000005115}
}

RIS

TY  - JOUR
TI  - Ekterly (sebetralstat) for hereditary angioedema: the first FDA-approved oral on-demand therapy
AU  - Dua Asim
AU  - Zoha Idrees
AU  - Muhammad Anas Faheem
AU  - Jaber Hamad Jaber Amin
PY  - 2026
JO  - Annals of Medicine & Surgery
DO  - 10.1097/ms9.0000000000005115
UR  - https://doi.org/10.1097/ms9.0000000000005115
ER  - 

APA

Asim, D., Idrees, Z., Faheem, M. A., & Amin, J. H. J. (2026). Ekterly (sebetralstat) for hereditary angioedema: the first FDA-approved oral on-demand therapy. Annals of Medicine & Surgery. https://doi.org/10.1097/ms9.0000000000005115

Source records